1-(3-Methylbutan-2-yl)-4-(trifluoromethyl)benzene | 1364858-50-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-(3-Methylbutan-2-yl)-4-(trifluoromethyl)benzene
• CAS: 1364858-50-3
• 化学式: C₁₂H₁₅F₃
• 分子量: 216.246
• InChiKey: DQTPJUOTVHEZHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对三氟甲基苯腈 在 正丁基锂 、 5%-palladium/activated carbon 、 氢气 、 copper(I) bromide 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 乙醇 、 正己烷 为溶剂， -78.0~60.0 ℃ 、405.33 kPa 条件下， 反应 26.83h， 生成 1-(3-Methylbutan-2-yl)-4-(trifluoromethyl)benzene
  参考文献：
  名称：

  EnantiopureC₁-Symmetric Bis(imino)pyridine Cobalt Complexes for Asymmetric Alkene Hydrogenation

  摘要：

  Enantiopure C-1-symmetric bis(imino)pyridine cobalt chloride, methyl, hydride, and cyclometalated complexes have been synthesized and characterized. These complexes are active as catalysts for the enantioselective hydrogenation of geminal-disubstituted olefins.

  DOI：

  10.1021/ja300503k

文献信息

• SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20210061802A1

  公开（公告）日：2021-03-04

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: R 1 , R 2 , R 4 , R 5 , and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了Formula (I)的化合物或其盐，其中：R1、R2、R4、R5和m在此处被定义。还揭示了使用这些化合物来抑制二酰甘油激酶α(DGKα)和二酰甘油激酶ζ(DGKζ)中的一个或两个活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面是有用的。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
  申请人：Rodgers D. James

  公开号：US20070135461A1

  公开（公告）日：2007-06-14

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可以调节雅努斯激酶的活性，并且在治疗与雅努斯激酶活性相关的疾病中具有用处，例如免疫相关疾病、皮肤疾病、髓增生性疾病、癌症和其他疾病。
• [EN] SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS<br/>[FR] COMPOSÉS QUINAZOLINYLE SUBSTITUÉS UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021133751A1

  公开（公告）日：2021-07-01

  Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: R1, R2, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα ) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  本文披露了Formula（I）的化合物：（I）或其盐，其中：R1、R2、R4、R5、R6和m在此处定义。同时还披露了使用这些化合物来抑制二酰基甘油激酶α（DGKα）和二酰基甘油激酶ζ（DGKζ）中一种或两种活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病，如癌症方面具有用途。
• HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090181959A1

  公开（公告）日：2009-07-16

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可调节Janus激酶的活性，并可用于治疗与Janus激酶活性相关的疾病，包括免疫相关疾病、皮肤疾病、髓系增生性疾病、癌症和其他疾病。
• Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  申请人：Rodgers James D.

  公开号：US20140018374A1

  公开（公告）日：2014-01-16

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯[2,3-b]吡啶和杂环取代的吡咯[2,3-b]嘧啶，其调节Janus激酶的活性，并且在治疗与Janus激酶活性相关的疾病中具有用处，包括但不限于免疫相关性疾病、皮肤疾病、髓样增生性疾病、癌症和其他疾病。